Insulet issues Omnipod 5 correction
Insulet initiated a voluntary medical device correction for select Omnipod 5 Pod lots after detecting a manufacturing quality issue, and the company's stock dipped on the news. The action highlights ongoing post‑market vigilance pressures and gives hospital procurement teams fresh data points when assessing infusion device reliability.
Insulet identified a small tear in the internal tubing that can cause insulin to leak inside affected Omnipod 5 pods investors.insulet.com, and the company reported 18 serious adverse-event reports tied to high blood glucose, including hospitalizations and diabetic ketoacidosis (DKA). investors.insulet.com The pods involved represent roughly 1.5% of annual Omnipod 5 pod production globally, according to Insulet’s notice, and the action covers specific lot numbers distributed only in the United States. investors.insulet.com Insulet told the SEC it currently expects to incur up to $40 million of costs related to the response in 2026 while excluding those costs from adjusted results and maintaining its prior guidance. sec.gov Shares slipped about 3% in Friday trading after the announcement as markets digested the operational and safety details, with commentators noting the move pushed the stock nearer to a 52‑week low. rttnews.com Insulet said it has implemented updates to manufacturing processes and quality controls, has notified the FDA, and is offering free replacements with customer lot‑check and support resources while continuing to manufacture and ship Omnipod 5 pods. investors.insulet.com
